COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,440 Articles (22,835 medRxiv, 8,605 bioRxiv)

Most recent first Previous |  Page 289: Articles 2881-2890  | Next

Investigating Sensitivity, Specificity and Accuracy of Variant Calling Pipelines for Analyzing SARS-CoV-2 Data
Krishna, A., Choi, J. S.
10.1101/2024.01.24.576385 — Posted: 2024-01-25
Interferon-γ as a Potential Inhibitor of SARS-CoV-2 ORF6 Accessory Protein
Krachmarova, E., Petkov, P., Lilkova, E., Stoynova, D., Malinova, K., Hristova, R., Gospodinov, A., Ilieva, N., Nacheva, G., Litov, L.
10.1101/2024.01.24.577015 — Posted: 2024-01-25
Longitudinal study of immunity to SARS-CoV2 in Ocrelizumab-treated multiple sclerosis patients up to 2 years after COVID-19 vaccination
Kister, I., Curtin, R., Piquet, A. L., Borko, T., Pei, J., Banbury, B. L., Bacon, T. E., Kim, A., Tuen, M., Velmurugu, Y., Nyovanie, S., Selva, S., Samanovic, M. I., Mulligan, M. J., Patskovsky, Y., Priest, J., Cabatingan, M., Winger, R. C., Krogsgaard, M., Silverman, G. J.
10.1101/2024.01.23.24301671 — Posted: 2024-01-24
Systemic SARS-CoV-2-specific antibody responses to infection and to COVID-19 and BCG vaccination
Claus, J., ten Doesschate, T., Taks, E., Debisarun, P. A., Smits, G., van Binnendijk, R., van der Klis, F., Verhagen, L. M., de Jonge, M. I., Bonten, M. J. M., Netea, M. G., van de Wijgert, J. H.
10.1101/2024.01.24.24301644 — Posted: 2024-01-24
Safety of BNT162b2 mRNA COVID-19 vaccine batches: A nationwide cohort study
Hviid, A., Bech Svalgaard, I.
10.1101/2024.01.22.24301520 — Posted: 2024-01-24
CD4+ and CD8+ T cells are required to prevent SARS-CoV-2 persistence in the nasal compartment
Kar, M., Johnson, K. E. E., Vanderheiden, A., Elrod, E. J., Floyd, K., Geerling, E., Stone, E. T., Salinas, E., Banakis, S., Wang, W., Sathish, S., Shrihari, S., Davis-Gardner, M. E., Kohlmeier, J., Pinto, A., Klein, R., Grakoui, A., Ghedin, E., Suthar, M. S.
10.1101/2024.01.23.576505 — Posted: 2024-01-24
Adaptive advantage of deletion repair in the N terminal domain of the SARS-CoV-2 spike protein in variants of concern
Alvarez-Herrera, M., Ruiz-Rodriguez, P., Navarro-Dominguez, B., Zulaica, J., Grau, B., Bracho, M. A., Guerreiro, M., Aguilar-Gallardo, C., Gonzalez-Candelas, F., Comas, I., Geller, R., Coscolla, M.
10.1101/2024.01.23.575696 — Posted: 2024-01-24
Patients with end-stage kidney disease and COVID-19 are commonly hospitalized early during COVID-19 illness: an opportunity for early intervention
Seethapathy, R., Wang, Q., Katz-Agranov, N., Strohbehn, I. A., Moreno, D., Harden, D., Bhattacharyya, R. P., Sise, M. E.
10.1101/2024.01.23.24301661 — Posted: 2024-01-23
Hybrid immunity to SARS-CoV-2 arises from serological recall of IgG antibodies distinctly imprinted by infection or vaccination
Voss, W. N., Mallory, M. A., Byrne, P. O., Marchioni, J. M., Knudson, S. A., Powers, J. M., Leist, S. R., Dadonaite, B., Townsend, D. R., Kain, J., Huang, Y., Satterwhite, E., Castillo, I. N., Mattocks, M., Paresi, C., Munt, J. E., Scobey, T., Seeger, A., Premkumar, L., Bloom, J. D., Georgiou, G., McLellan, J. S., Baric, R. S., Lavinder, J. J., Ippolito, G. C.
10.1101/2024.01.22.576742 — Posted: 2024-01-23
SOX9-regulated matrix proteins predict poor outcomes in patients with COVID-19 and pulmonary fibrosis
Pearmain, L., Jokl, E., Simpson, K., Birchall, L., Ou, Y., Lawless, C., Simpson, A., Mann, E., Scott, N. A., Shah, R., Venkateswaran, R., Stanel, S., Hayton, C., Rivera-Ortega, P., Hansbro, P., Hanley, N., Blaikley, J. A., Piper Hanley, K.
10.1101/2024.01.21.576509 — Posted: 2024-01-23

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).